What is Ocugen's gross profit margin?

What guidance did Ocugen's management provide for the next earnings period?

What does Ocugen do and what are its main business segments?

What were the key takeaways from Ocugen's earnings call?

What were the key takeaways from Ocugen’s earnings call?

What is the revenue and EPS growth rate for Ocugen year over year?

What is the market's earnings forecast for Ocugen next quarter?

What is Ocugen's latest dividend and current dividend yield?

- **Clinical Milestones**: OCU400 Phase 3 nearing completion, with BLA submission in 2026. OCU410ST 50% enrolled in Phase 2/3, targeting 51 subjects. OCU410 shows 23% lesion reduction in Phase 1,优于现有疗法.
- **Partnerships & Funding**: $7.5M deal with Kwangdong for South Korea rights; $20M financing extends runway to Q2 2026. European MAA submission aligned with U.S. timeline.
- **Manufacturing Readiness**: Process validation on track; U.S. manufacturing site to support 2027 launch.
- **Market Potential**: OCU400 addresses 300,000 RP patients in U.S./Europe; OCU410 targets 2-3 million GA patients globally.

**【CEO Summary Section】**
- **OCU400 Phase 3 Progress**: Enrollment nearing completion for the liMeLiGhT trial, with BLA submission planned for 2026. OCU400 targets 98% of RP patients, addressing multiple genetic mutations with a single therapy. Phase 3 is the largest orphan gene therapy trial, with 150 subjects (100 treated, 50 control). 12-month data release expected Q4 2026.
- **OCU410ST Update**: Phase 2/3 GARDian3 trial 50% enrolled, targeting 51 subjects (34 treated, 17 control). CHMP accepted U.S. trial data for MAA submission, aligning timelines with OCU400. 12-month Phase 1 data showed 48.2% lesion growth reduction and visual acuity gains.
- **OCU410 for GA**: 12-month Phase 1 data shows 23% lesion growth reduction, outperforming existing therapies. Phase 2/3 planned for 2026, targeting 2-3 million GA patients globally.
- **Partnerships**: $7.5M deal with Kwangdong Pharmaceutical for OCU400 in South Korea, with $1.5M per $15M sales milestone and 25% royalty. European MAA submission aligned with U.S. timeline.
- **Manufacturing**: Process validation runs on track; U.S. manufacturing site in Malvern, PA, to support 2027 commercial launch.

**【CFO Financial Commentary】**
- **Cash Position**: $32.9M as of Q3 2025, down from $58.8M in Q4 2024. Recent $20M financing extends runway to Q2 2026; $30M warrant exercise could extend to 2027.
- **Operating Expenses**: Q3 2025 total $19.4M (R&D: $11.2M, G&A: $8.2M), up 34% YoY. Focus on clinical trial costs and commercial preparation.

**【Q&A Highlights】**
- **BLA Timeline**: Rolling submission for OCU400 BLA to begin H1 2026, with full submission late 2026. Manufacturing material ready for commercial use.
- **Trial Design**: OCU400 Phase 3 includes untreated control group for direct comparison; 97% statistical power. OCU410ST interim data mid-2026 will include lesion growth and visual acuity metrics.
- **Commercial Strategy**: U.S. commercialization ramp-up with regional partnerships; South Korea deal preserves global rights. European MAA submission aligned with U.S. timeline.
- **Manufacturing Capacity**: Ex-U.S. partner provides sufficient capacity; U.S. site to be FDA-approved by 2027.
- **LCA Program**: Not prioritized due to small market size; potential Phase 4 evaluation post-RP launch.

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

- **Pipeline Momentum**: OCU400 Phase III trial shows 27% lesion growth reduction; OCU410ST Stargardt trial enrolling first patients. OCU410 GA data demonstrates 23% slower lesion growth.
- **Strategic Deals**: $11M Korean partnership and $135M OrthoCellix spin-off enhance capital flexibility.
- **Financial Health**: $27.3M cash with $15.2M Q2 expenses; exploring partnerships to minimize dilution.
- **Regulatory Clarity**: EMA MAA eligibility for OCU400; Korea may approve using U.S. data.

**【CEO Summary Section】**
- **Gene Therapy Pipeline Progress**: OCU400 Phase III trial for RP is on track for BLA/MAA filings in 2026, with 27% lesion growth reduction in GA at 6 months. OCU410ST Stargardt trial dosed first patient in July 2025, targeting 44,000 U.S. patients with no approved treatments. OCU410 for GA shows 23% slower lesion growth at 12 months vs. untreated eyes.
- **Strategic Partnerships**: Signed term sheet for Korean rights to OCU400, expected to close by September 2025. Spun off NeoCart into OrthoCellix, valued at $135M, to focus on orthopedic cell therapy.
- **Leadership Changes**: Appointed Vijay Tammara as Chief Development Officer and Abhi Gupta as EVP of Commercial & Business Development to accelerate commercialization.

**【CFO Financial Commentary】**
- **Cash Position**: $27.3M as of Q2 2025, down from $58.8M at year-end 2024.
- **Operating Expenses**: $15.2M for Q2 2025 (R&D: $8.4M, G&A: $6.8M), down 8% YoY.
- **Partnership Revenue**: $11M from Korean deal to be recognized over 2025-2027.

**【Q&A Highlights】**
- **Clinical Enrollment**: Stargardt trial has 15 activated sites and no enrollment challenges despite disease rarity. GA trial interim data at 9-12 months expected Q4 2025.
- **Regulatory Path**: EMA granted MAA eligibility for OCU400; Korea may approve using U.S. data. FDA supportive of Stargardt trial timeline.
- **Financial Strategy**: Pursuing nondilutive funding via partnerships; exploring equity options if needed.

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

- **3 Pipeline Milestones**: OCU400 (BLA 2026), OCU410ST (BLA 2027), OCU410 (BLA 2028) on track for 3 BLA filings by 2028.
- **Clinical Success**: OCU400 Phase 1/2 shows 100% treated eyes improved; OCU410ST Phase 1 shows 54% slower lesion growth.
- **Financial Position**: $38.1M cash, runway to Q1 2026; R&D spend up 40% to $9.5M reflecting clinical acceleration.
- **Manufacturing Scale**: Malvern GMP facility ready for US launch 2027; process validation on track for 2025.


**【CEO Business Update】**
- **OCU400 for RP**: Phase 3 trial enrolling 150 patients with 2-year data showing 100% of treated eyes improved or preserved visual function. EMA granted MAA eligibility for 2026 submission. 
- **OCU410ST for Stargardt**: FDA-aligned Phase 2/3 trial to start Q2 2025 with 51 subjects. 12-month Phase 1 data shows 54% slower atrophic lesion growth. BLA target 2027.
- **OCU410 for GA**: Phase 2 dosing complete with 41% slower lesion growth vs untreated. Phase 3 planned 2026, BLA 2028.
- **Manufacturing**: Process validation on track for 2025. Malvern GMP facility to support US commercial launch 2027+.

**【CFO Financial Update】**
- Q1 2025: 
  - R&D Expenses: $9.5M (vs $6.8M Q1 2024)
  - G&A Expenses: $6.5M (flat vs prior year)
  - Net Loss: $15.3M ($0.05/share) vs $11.9M ($0.05) prior year
  - Cash: $38.1M (down from $58.8M)
- Cash runway into Q1 2026. Exploring strategic funding options.

**【Key Q&A Highlights】**
- **OCU400 Enrollment**: Phase 3 on track for H1 2025 enrollment, BLA submission 2026.
- **Manufacturing Strategy**: Partnering with CanSinoBio for initial supply, in-house Malvern facility to follow.
- **OCU200 Update**: Phase 1 trial completion expected Q4 2025 with preliminary data release.
- **Flu Vaccine (OCU500)**: NIAID Phase 1 trial on track for Q2 2025 start, no regulatory delays noted.


Ocugen (OCGN)-9 May 25-2025 Q1 Earnings call transcript

- **3 BLAs by 2028**: OCU400 (2026), OCU410ST (2027), OCU410 (2028) with FDA-aligned trials and ATMP classifications.
- **Clinical Milestones**: OCU400 Phase III enrollment on track for 2025; OCU410ST Phase II/III starts mid-2025; OCU410 interim data H2 2025.
- **Cash Runway**: $58.8M supports operations into Q1 2026; 2024 financings extend liquidity.
- **Innovative Pipeline**: OCU200 targets anti-VEGF non-responders; OCU500 inhaled COVID vaccine Phase I expected Q2 2025.
- **Strategic Pricing**: Gene therapy one-time cost vs. annual injections; CMS discussions for GA indication.


**【CEO Business Update】**
- **OCU400 (Retinitis Pigmentosa)**: Phase III trial enrolling 150 patients with 2-year durability data showing 2-line gain in low luminance visual acuity (LLVA). Targeting BLA submission in mid-2026. European Medicines Agency (EMA) granted Advanced Therapy Medicinal Product (ATMP) classification, accelerating regulatory timeline.
- **OCU410ST (Stargardt Disease)**: FDA-aligned Phase II/III pivotal trial to start mid-2025 with 51 patients. 6-month data shows 2-line improvement in best corrected visual acuity (BCVA) and 52% slower atrophic lesion growth. Targeting BLA submission in 2027.
- **OCU410 (Geographic Atrophy)**: Phase II trial completed recruitment; interim data expected H2 2025. 9-month data shows 44% slower lesion growth vs. untreated eyes. Targeting BLA submission in 2028.
- **OCU200 (Diabetic Macular Edema)**: Phase I trial dosing patients with 3 dose cohorts. Potential to address 30%-40% of anti-VEGF non-responders.
- **OCU500 (COVID-19 Vaccine)**: FDA-cleared IND for inhaled/intranasal delivery. Phase I trial expected Q2 2025, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

**【CFO Financial Summary】**
- **Q4 2024**: R&D expenses $8.3M, G&A $6.3M, net loss $13.9M. Full year 2024: R&D $32.1M, G&A $26.7M, net loss $54.1M.
- **Cash Position**: $58.8M as of Dec 31, 2024, providing runway into Q1 2026. 2024 equity/debt financings of $65M extended cash runway.
- **Funding Strategy**: Exploring partnerships and shareholder-friendly opportunities to support clinical pipeline.

**【Q&A Highlights】**
- **Runway & New Trials**: 2025 Phase II/III OCU410ST trial costs already budgeted within $58.8M cash runway.
- **DME Program**: OCU200 Phase I safety and efficacy data expected end-2025; exploring BCVA and antibody response endpoints.
- **COVID Vaccine**: NIAID confirms Phase I on track for Q2 2025 start, with NIH funding for trial.
- **BLA Confidence**: Track record of rapid clinical execution (e.g., OCU400 Phase I/II completed in 3 years) and FDA alignment on trial designs.
- **Pricing Strategy**: Fair pricing for one-time gene therapy vs. annual anti-VEGF injections; CMS reimbursement discussions ongoing.
- **Manufacturing Scale**: Commercial-grade manufacturing used in Phase I for OCU410ST, same strategy as OCU400.
- **Site Selection**: U.S.-based recruitment for OCU410ST due to sufficient patient population; no international sites needed.


OCGN

OCGN fundamentals

Earnings Call

You can ask Aime